Neuronetics Q2 Earnings Call Highlights
Neuronetics (NASDAQ:STIM) reported Q2 Worldwide NeuroStar revenue of $14.7M, down 2.7% YoY, with capital revenue up and treatment-session revenue down. The company expanded NeuroStar purchase and leasing options, expects no further material inventory reduction in H2, and plans to report NeuroStar as a single revenue line. Gross margin rose to 61.1% and 2026 guidance was narrowed to $160M-$164M.
How this was made
The 30-second read
Why it matters
Traders can update models around 2026 profitability targets (gross margin and operating expense) and reassess second-half revenue volatility risk tied to new purchase and leasing options and session utilization dynamics.
Market read
STIM’s guidance update and margin/expense/cash improvements are the main tradable catalysts, with added uncertainty from second-half revenue mix shifts and new revenue reporting structure.
What to watch
Management’s warning about “choppier” second-half revenue and the planned change to reporting NeuroStar as a single revenue line could complicate trend analysis and increase near-term forecast error.
Background
The piece summarizes Neuronetics’ Q2 earnings call, focusing on NeuroStar revenue model changes, margin/expense/cash performance, and updated 2026 guidance.
Ticker impact
Neuronetics reported Q2 results and updated 2026 guidance, including narrower revenue range, higher gross margin, and lower operating expense outlook.
Moderate positive bias for STIM as higher gross margin and lower opex guidance improve earnings visibility, but second-half revenue “choppiness” and mix changes add volatility.
The article discloses multiple forward-looking datapoints: narrowed revenue guidance ($160M-$164M), gross margin raised (48%-50%), operating expense lowered ($95M-$100M), and cash increased with an ATM raise. It also flags potential second-half revenue variability from new commercial models and reporting NeuroStar as a single revenue line, which can affect investor interpretation of capital vs session trends.
Market effects
Improved rTMS equipment economics and a shift toward purchase/lease models may influence sentiment around neuromodulation commercialization and payer-driven revenue capture.
Limited, company-specific US small-cap medical device read-through.
Low, no cross-border deal or regulatory action disclosed.
Counterpoint
The gross margin jump could be mix-driven and may not persist if session-to-capital/lease mix continues to shift, making the profitability improvement less durable than it appears.
Key entities
- companyNeuronetics
Commercial-stage rTMS medical technology company; flagship NeuroStar system and Greenbrook network.
- productNeuroStar
rTMS Advanced Therapy System; revenue will be reported as a single line going forward.
- business_unitGreenbrook
Treatment network where patient qualification, claims processing, and collections improved revenue capture.
- companyCompass Pathways
Referenced for potential commercial launch preparations of a psychedelic therapy, subject to Compass regulatory process.
